7.95
-0.22(-2.69%)
Currency In USD
| Previous Close | 8.17 |
| Open | 8.19 |
| Day High | 8.43 |
| Day Low | 7.95 |
| 52-Week High | 8.98 |
| 52-Week Low | 3.85 |
| Volume | 171,880 |
| Average Volume | 520,806 |
| Market Cap | 639.3M |
| PE | -3.92 |
| EPS | -2.03 |
| Moving Average 50 Days | 7.53 |
| Moving Average 200 Days | 6.58 |
| Change | -0.22 |
If you invested $1000 in MeiraGTx Holdings plc (MGTX) since IPO date, it would be worth $530 as of August 18, 2025 at a share price of $7.95. Whereas If you bought $1000 worth of MeiraGTx Holdings plc (MGTX) shares 5 years ago, it would be worth $564.23 as of August 18, 2025 at a share price of $7.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
GlobeNewswire Inc.
May 13, 2025 8:30 PM GMT
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
GlobeNewswire Inc.
May 09, 2025 12:00 PM GMT
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy desi
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
GlobeNewswire Inc.
Mar 13, 2025 11:30 AM GMT
- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Par